MX359656B - Derivados de oxoquinazolinil-butanamida. - Google Patents
Derivados de oxoquinazolinil-butanamida.Info
- Publication number
- MX359656B MX359656B MX2016001136A MX2016001136A MX359656B MX 359656 B MX359656 B MX 359656B MX 2016001136 A MX2016001136 A MX 2016001136A MX 2016001136 A MX2016001136 A MX 2016001136A MX 359656 B MX359656 B MX 359656B
- Authority
- MX
- Mexico
- Prior art keywords
- oxoquinazolinyl
- butanamide derivatives
- diseases
- butanamide
- derivatives
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 102000004535 Tankyrases Human genes 0.000 abstract 1
- 108010017601 Tankyrases Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la fórmula I (ver Fórmula) en donde R1-R3 y Z tienen los significados indicados en la reivindicación 1, son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003815 | 2013-07-31 | ||
| PCT/EP2014/001895 WO2015014442A1 (en) | 2013-07-31 | 2014-07-10 | Oxoquinazolinyl-butanamide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001136A MX2016001136A (es) | 2016-04-29 |
| MX359656B true MX359656B (es) | 2018-10-05 |
Family
ID=48915813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001136A MX359656B (es) | 2013-07-31 | 2014-07-10 | Derivados de oxoquinazolinil-butanamida. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9901577B2 (es) |
| EP (1) | EP3027598B1 (es) |
| JP (1) | JP6423875B2 (es) |
| KR (1) | KR102331389B1 (es) |
| CN (1) | CN105392784B (es) |
| AR (1) | AR097087A1 (es) |
| AU (1) | AU2014298955B2 (es) |
| BR (1) | BR112016001645B1 (es) |
| CA (1) | CA2919905C (es) |
| DK (1) | DK3027598T3 (es) |
| ES (1) | ES2632988T3 (es) |
| HR (1) | HRP20171053T1 (es) |
| HU (1) | HUE032846T2 (es) |
| IL (1) | IL243734B (es) |
| LT (1) | LT3027598T (es) |
| MX (1) | MX359656B (es) |
| NZ (1) | NZ716593A (es) |
| PL (1) | PL3027598T3 (es) |
| PT (1) | PT3027598T (es) |
| RS (1) | RS56211B1 (es) |
| RU (1) | RU2669393C2 (es) |
| SG (1) | SG11201600743WA (es) |
| SI (1) | SI3027598T1 (es) |
| WO (1) | WO2015014442A1 (es) |
| ZA (1) | ZA201601333B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201609205WA (en) | 2014-05-07 | 2016-12-29 | Merck Patent Gmbh | Heterocyclyl-butanamide derivatives |
| RU2018119935A (ru) * | 2015-11-02 | 2019-12-04 | Мерк Патент Гмбх | 1,4-дикарбонилпиперидильные производные |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201615282D0 (en) * | 2016-09-08 | 2016-10-26 | Univ Bath | Tankyrase inhibitors |
| AU2017388376B2 (en) * | 2016-12-30 | 2022-01-06 | Mitobridge, Inc. | Poly-ADP ribose polymerase (PARP) inhibitors |
| CA3085353A1 (en) * | 2017-12-21 | 2019-06-27 | Ribon Therapeutics Inc. | Quinazolinones as parp14 inhibitors |
| CN109180702B (zh) * | 2018-10-29 | 2021-11-30 | 四川大学 | 一种噻吩并嘧啶酮化合物及其用途 |
| EP3891136B1 (en) | 2018-12-03 | 2023-07-19 | Merck Patent GmbH | 4-heteroarylcarbonyl-n-(phenyl or heteroaryl)piperidine-1-carboxamides as inhibitors of tankyrases |
| CN115335371B (zh) * | 2020-03-19 | 2024-12-27 | 默克专利股份公司 | 四唑衍生物 |
| WO2023161881A1 (en) * | 2022-02-25 | 2023-08-31 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for ccr2-expressing cells |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202915D0 (en) * | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| US6596700B2 (en) * | 2000-05-26 | 2003-07-22 | Idenix Pharmaceuticals Inc. | Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| EP1633724B1 (en) * | 2003-03-12 | 2011-05-04 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| CA2569826C (en) | 2004-06-30 | 2013-07-16 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| CN101492425A (zh) * | 2009-02-27 | 2009-07-29 | 无锡市凯奥善生物医药科技有限公司 | 一类parp抑制剂的化合物 |
| EP2731942B1 (en) | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
-
2014
- 2014-07-10 PT PT147390454T patent/PT3027598T/pt unknown
- 2014-07-10 NZ NZ716593A patent/NZ716593A/en not_active IP Right Cessation
- 2014-07-10 RS RS20170679A patent/RS56211B1/sr unknown
- 2014-07-10 WO PCT/EP2014/001895 patent/WO2015014442A1/en not_active Ceased
- 2014-07-10 KR KR1020167005040A patent/KR102331389B1/ko not_active Expired - Fee Related
- 2014-07-10 HR HRP20171053TT patent/HRP20171053T1/hr unknown
- 2014-07-10 EP EP14739045.4A patent/EP3027598B1/en active Active
- 2014-07-10 DK DK14739045.4T patent/DK3027598T3/da active
- 2014-07-10 SG SG11201600743WA patent/SG11201600743WA/en unknown
- 2014-07-10 CA CA2919905A patent/CA2919905C/en active Active
- 2014-07-10 LT LTEP14739045.4T patent/LT3027598T/lt unknown
- 2014-07-10 BR BR112016001645-9A patent/BR112016001645B1/pt not_active IP Right Cessation
- 2014-07-10 MX MX2016001136A patent/MX359656B/es active IP Right Grant
- 2014-07-10 RU RU2016106952A patent/RU2669393C2/ru active
- 2014-07-10 JP JP2016530371A patent/JP6423875B2/ja not_active Expired - Fee Related
- 2014-07-10 PL PL14739045T patent/PL3027598T3/pl unknown
- 2014-07-10 HU HUE14739045A patent/HUE032846T2/en unknown
- 2014-07-10 US US14/909,365 patent/US9901577B2/en active Active
- 2014-07-10 AU AU2014298955A patent/AU2014298955B2/en not_active Ceased
- 2014-07-10 SI SI201430283T patent/SI3027598T1/sl unknown
- 2014-07-10 CN CN201480042153.0A patent/CN105392784B/zh not_active Expired - Fee Related
- 2014-07-10 ES ES14739045.4T patent/ES2632988T3/es active Active
- 2014-07-28 AR ARP140102799A patent/AR097087A1/es active IP Right Grant
-
2016
- 2016-01-21 IL IL243734A patent/IL243734B/en active IP Right Grant
- 2016-02-26 ZA ZA2016/01333A patent/ZA201601333B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359656B (es) | Derivados de oxoquinazolinil-butanamida. | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| MX357502B (es) | Derivados de pirrolotriazinona. | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| NZ720478A (en) | Autotaxin inhibitor compounds | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| MX371108B (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| MX366140B (es) | Derivados de urea de piperidinas. | |
| MX2016001134A (es) | Derivados 1,3-disustituidos de ciclopentano. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| MX364859B (es) | Derivados de imidazopirazinona. | |
| MX2018003860A (es) | Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |